Mayne Pharma share price on watch ahead of AGM update

The Mayne Pharma Ltd (ASX: MYX) share price is on watch on the ASX after a trading update from the company's annual general meeting (AGM).

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mayne Pharma Group Ltd (ASX: MYX) share price is on watch this morning ahead of the company's annual general meeting (AGM).

What could move the Mayne Pharma share price?

Mayne Pharma provided an update on its FY20 trading performance so far.

The US generic pharmaceuticals market "continues to have challenging dynamics", according to CEO Scott Richards.

Aggressive contracting behaviour from three major buying groups that control 90% of retail generic drug purchasing are behind the market headwinds.

Mr. Richards said price deflation and volume has been evident in the market since it peaked in 2016.

The Mayne Pharma share price will be one to watch, given the softer conditions forecast for the short to mid-term as it looks to move away from the generics sector.

The company's focus is on rebalancing its portfolio to better protect and grow sustainable revenue and profit streams.

What about Mayne Pharma's revenues?

Group revenue for the four months in FY20 is down 16% from last year to $153 million. Mayne Pharma reported lower gross margin due to a changed sales mix and inventory obsolescence from generics. 

Generics Production Division revenue growth was down 26% on the prior corresponding period (pcp) but flat on the first four months of 2019.

The realignment of the business is expected to provide a boost with Mayne Pharma's women's health portfolio growing 50% on pcp.

The company's Metrics Contract Services grew revenue by 16% on pcp to $26 million.

Mayne Pharma is bullish on its new E4/DRSP oral contraceptive product after announcing a deal with Mithra Pharmaceuticals in the United States.

Investors will be hoping to see a boost for the Mayne Pharma share price in 2021 when sales of the new product are expected to begin.

What about Mayne Pharma's outlook?

Volatility in results has been a factor in recent years due to FDA approvals, competitor launches and withdrawals of key products.

Mayne Pharma therefore declined to provide earnings guidance for FY20 for those reasons.

Mr. Richards noted the company's strong generics pipeline and the focus on growing its women's health portfolio into 2020.

The Mayne Pharma share price will be worth watching this morning given the headwinds cited by management today.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »